Current Geriatrics Reports

, Volume 6, Issue 1, pp 20–25 | Cite as

Post-Polio Syndrome, Implications for Geriatric Care

Infectious Diseases in the Elderly (M. Schilling, Section Editor)
  • 116 Downloads
Part of the following topical collections:
  1. Topical Collection on Infectious Diseases in the Elderly

Abstract

Purpose of Review

Post-polio syndrome (PPS) is commonly experienced by geriatric patients with a history of acute paralytic poliomyelitis. The goal of this review is to educate clinicians about the clinical presentation and diagnostic criteria for PPS as well as explore established and experimental treatment options.

Recent Findings

On review of the literature, there is no new research identifying effective interventions for PPS.

Summary

The paucity of recent studies is not surprising since polio patients are diminishing in number. There is some hope that interventions for other similar conditions may cross over and show some utility for PPS. In lieu of further treatment options, clinicians should be comfortable educating their patients on the course of the disease and providing supportive management such as physical therapy and bracing.

Keywords

Post-polio syndrome Post-poliomyelitis syndrome 

Notes

Compliance with Ethical Standards

Conflict of Interest

Thomas McNalley did fill out his conflict of interest form and likely has no conflict of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •of importance

  1. 1.
    Halstead LS. Assessment and differential diagnosis for post-polio syndrome. Orthopedics. 1991;14(11):1209–17.PubMedGoogle Scholar
  2. 2.
    Farbu E, Gilhus NE, Barnes MP, Borg K, de Visser M, Driessen A, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol. 2006;13(8):795–801.CrossRefPubMedGoogle Scholar
  3. 3.
    Tracking progress towards global polio eradication, 2010–2011. Weekly epidemiological record: Relevé épidémiologique hebdomadaire. Geneva: World Health Organization. 2012 April;87:153–160. Available from: http://www.who.int/wer/2012/wer8716.pdf
  4. 4.
    Becker LC. Polio survivors in the US 1915–2000 age distribution data [Internet]. Post-polio health international [cited 2016 Oct 1]. Available from: http://www.post-polio.org/PoliosurvivorsintheUS1915-2000.pdf
  5. 5.
    Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci. 1995;50 Spec No:107–12.PubMedGoogle Scholar
  6. 6.
    Schanke AK, Stanghelle JK. Fatigue in polio survivors. Spinal Cord. 2001;39(5):243–51.CrossRefPubMedGoogle Scholar
  7. 7.
    • Koopman FS, Beelen A, Gilhus NE, de Visser M, Nollet F. Treatment for postpolio syndrome. Cochrane Database Syst Rev. 2015;5:CD007818. Updated assessment of research for treatment of PPS Google Scholar
  8. 8.
    Gonzalez H, Khademi M, Borg K, Olsson T. Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up. J Neuroinflammation. 2012;9:167.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 2006;5(6):493–500.CrossRefPubMedGoogle Scholar
  10. 10.
    Kaponides G, Gonzalez H, Olsson T, Borg K. Effect of intravenous immunoglobulin in patients with post-polio syndrome—an uncontrolled pilot study. J Rehabil Med. 2006;38(2):138–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol. 2007;14(1):60–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Ostlund G, Broman L, Werhagen L, Borg K. IVIG treatment in post-polio patients: evaluation of responders. J Neurol. 2012;259(12):2571–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Bertolasi L, Acler M, dall’ora E, Gajofatto A, Frasson E, Tocco P, et al. Risk factors for post-polio syndrome among an Italian population: a case-control study. Neurol Sci. 2012;33(6):1271–5.CrossRefPubMedGoogle Scholar
  14. 14.
    • Huang YH, Chen HC, Huang KW, Chen PC, Hu CJ, Tsai CP, et al. Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis. BMC Neurol. 2015;15:39. Determines that IVIg confers no clear benefit in PPS CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chan KM, Strohschein FJ, Rydz D, Allidina A, Shuaib A, Westbury CF. Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients. Muscle Nerve. 2006;33(1):138–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Vasconcelos OM, Prokhorenko OA, Salajegheh MK, Kelley KF, Livornese K, Olsen CH, et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology. 2007;68(20):1680–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Horemans HL, Nollet F, Beelen A, Drost G, Stegeman DF, Zwarts MJ, et al. Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. J Neurol Neurosurg Psychiatry. 2003;74(12):1655–61.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    On AY, Oncu J, Uludag B, Ertekin C. Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study. NeuroRehabilitation. 2005;20(4):245–51.PubMedGoogle Scholar
  19. 19.
    Stein DP, Dambrosia JM, Dalakas MC. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann N Y Acad Sci. 1995;753:296–302.CrossRefPubMedGoogle Scholar
  20. 20.
    Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W. A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis. Complement Ther Med. 2015;23(6):789–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Dinsmore S, Dambrosia J, Dalakas MC. A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann N Y Acad Sci. 1995;753:303–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Acler M, Bocci T, Valenti D, Turri M, Priori A, Bertolasi L. Transcranial direct current stimulation (tDCS) for sleep disturbances and fatigue in patients with post-polio syndrome. Restor Neurol Neurosci. 2013;31(5):661–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.University of WashingtonSeattleUSA
  2. 2.Kaiser PermanenteOaklandUSA

Personalised recommendations